首页 News 正文

On November 5th, the opening day of the 7th CIIE, Pfizer announced that its innovative drug, Terazopanib Tosylate Capsules (trade name: Taizena), has recently been approved for market by the National Medical Products Administration (NMPA). It is used in combination with enzalutamide to treat adult patients with metastatic castration resistant prostate cancer (mCRPC) and HRR (homologous recombination repair) gene mutations, orally once a day. This is currently the only PARP inhibitor approved for the treatment of mCRPC with HRR gene mutations in China.
We are also very lucky, "said Wang Yu, Vice President of Pfizer China and General Manager of the Oncology Division, in an interview with Time Finance during this year's CIIE
Professor Ye Dingwei, Vice President of Fudan University Affiliated Cancer Hospital and Director of Shanghai Institute of Urology and Oncology, cited the latest clinical research data and pointed out that the combination of tazolazopanib tosylate and enzalutamide treatment can significantly improve the clinical outcomes of mCRPC patients with HRR gene mutations. Compared with placebo combined with enzalutamide treatment, the combination of tacrolizumab and enzalutamide significantly prolonged rPFS (NR vs 13.8 months, HR: 0.45 (0.33-0.61)).
As of now, Taizena has been granted priority review qualification by the US Food and Drug Administration (FDA), and has obtained marketing authorization from multiple regions around the world such as the United States, the European Union, and Japan. It has also been unanimously recommended by authoritative guidelines at home and abroad, including the National Comprehensive Cancer Network (NCCN), the European Association of Urology (EAU), and the Chinese Society of Clinical Oncology (CSCO). Approved in China this time, Taizena will help make breakthroughs in precision diagnosis and treatment of prostate cancer in China, providing more choices for Chinese mCRPC patients with HRR gene mutations who urgently need personalized treatment.
In addition, Pfizer also showcased 24 globally leading innovative products and solutions in the fields of oncology, anti infection, inflammation and immunity, rare diseases, migraine, vaccines, etc. during this year's CIIE. Among them, 4 of them made their debut in China, including the world's first β - lactam/β - lactam inhibitor combination injection of tranexamic avibactam sodium (trade name: Sifono) targeting metal β - lactam enzymes (MBLs), hemophilia therapy Mataximab, and bispecific antibody Enanto monoclonal antibody targeting B cell mature antigen and CD3.
We also look forward to receiving industry attention through the exposure of multiple products at the CIIE, and promoting the rapid approval and launch of products in China. Wang Yu further told Time Finance that from the perspective of layout, Pfizer hopes to make people aware of the visibility of cancer through cancer visualization, which also needs everyone's understanding. In fact, everyone should unite to fight cancer, so that more people can face cancer directly, and at the same time, cooperate with innovative drugs and other treatment plans to strive to overcome cancer.
With China becoming a crucial part of the global pharmaceutical industry chain, the Chinese market has become a battleground for multinational pharmaceutical companies. With the spillover effect of the CIIE, multinational pharmaceutical companies have been increasing their investment in the Chinese market.
According to Pfizer China's 2030 strategy, Pfizer's newly established R&D center in Beijing will upgrade Pfizer's existing global innovative drug research and development layout in China, and play a leading role in Pfizer's innovative drug development in China, promoting the efficient implementation of the China Al In strategy and including China in the early clinical stages of Pfizer's innovative drugs and vaccines, as well as the global synchronous development of all key Phase 3 studies.
Wang Yu explained to Time Finance, "The China Al In strategy means that China will be included in all of our key clinical registrations worldwide. For example, whether our products are listed in the United States or Europe, China will default to the registration process. We hope that all Chinese product pipelines will be consistent with the global product pipeline. In addition, the China Al In strategy is also related to accelerating the introduction. All of our products participating in international clinical registrations will ensure synchronization in the pace of domestic approval as much as possible
With the continuous changes in China's pharmaceutical policies, pharmaceutical companies not only need to consider drug research and approval in the front-end, but also need to consider how to better benefit patients after commercialization. Our country's healthcare system reform has been constantly advancing, and we should take a positive view and respond to these policies in a practical way. We should be good at digging machines, "Wang Yu told Time Finance.
Wang Yu stated that Pfizer hopes to explore more flexible and diverse payment methods to truly lower the affordability threshold for innovative drugs. When diseases strike, there is no distinction between poverty and wealth, so regardless of where patients are or their economic status, they should enjoy the same treatment plan. We hope to make every effort to promote fairness in cancer diagnosis and treatment
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

外汇之门 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    0